tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2020 Oct 25;8(4):E626.
doi: 10.3390/vaccines8040626.
Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness
Po-Ling Chen[SUP] 1 2 [/SUP], Tsai-Teng Tzeng[SUP] 1 [/SUP], Alan Yung-Chih Hu[SUP] 1 [/SUP], Lily Hui-Ching Wang[SUP] 2 [/SUP], Min-Shi Lee[SUP] 1 [/SUP]
Affiliations
Abstract
The embryonated egg-based platform currently produces the majority of seasonal influenza vaccines by employing a well-developed master donor virus (MDV, A/PR/8/34 (PR8)) to generate high-growth reassortants (HGRs) for A/H1N1 and A/H3N2 subtypes. Although the egg-based platform can supply enough seasonal influenza vaccines, it cannot meet surging demands during influenza pandemics. Therefore, multi-purpose platforms are desirable for pandemic preparedness. The Vero cell-based production platform is widely used for human vaccines and could be a potential multi-purpose platform for pandemic influenza vaccines. However, many wild-type and egg-derived influenza viruses cannot grow efficiently in Vero cells. Therefore, it is critical to develop Vero cell-derived high-growth MDVs for pandemic preparedness. In this study, we evaluated two in-house MDVs (Vero-15 and VB5) and two external MDVs (PR8 and PR8-HY) to generate Vero cell-derived HGRs for five avian influenza viruses (AIVs) with pandemic potentials (H5N1 clade 2.3.4, H5N1 clade 2.3.2.1, American-lineage H5N2, H7N9 first wave and H7N9 fifth wave). Overall, no single MDV could generate HGRs for all five AIVs, but this goal could be achieved by employing two in-house MDVs (vB5 and Vero-15). In immunization studies, mice received two doses of Vero cell-derived inactivated H5N1 and H7N9 whole virus antigens adjuvanted with alum and developed robust antibody responses.
Keywords: Vero cell-derived influenza vaccine; master donor virus; pandemic preparedness.
. 2020 Oct 25;8(4):E626.
doi: 10.3390/vaccines8040626.
Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness
Po-Ling Chen[SUP] 1 2 [/SUP], Tsai-Teng Tzeng[SUP] 1 [/SUP], Alan Yung-Chih Hu[SUP] 1 [/SUP], Lily Hui-Ching Wang[SUP] 2 [/SUP], Min-Shi Lee[SUP] 1 [/SUP]
Affiliations
- PMID: 33113866
- DOI: 10.3390/vaccines8040626
Abstract
The embryonated egg-based platform currently produces the majority of seasonal influenza vaccines by employing a well-developed master donor virus (MDV, A/PR/8/34 (PR8)) to generate high-growth reassortants (HGRs) for A/H1N1 and A/H3N2 subtypes. Although the egg-based platform can supply enough seasonal influenza vaccines, it cannot meet surging demands during influenza pandemics. Therefore, multi-purpose platforms are desirable for pandemic preparedness. The Vero cell-based production platform is widely used for human vaccines and could be a potential multi-purpose platform for pandemic influenza vaccines. However, many wild-type and egg-derived influenza viruses cannot grow efficiently in Vero cells. Therefore, it is critical to develop Vero cell-derived high-growth MDVs for pandemic preparedness. In this study, we evaluated two in-house MDVs (Vero-15 and VB5) and two external MDVs (PR8 and PR8-HY) to generate Vero cell-derived HGRs for five avian influenza viruses (AIVs) with pandemic potentials (H5N1 clade 2.3.4, H5N1 clade 2.3.2.1, American-lineage H5N2, H7N9 first wave and H7N9 fifth wave). Overall, no single MDV could generate HGRs for all five AIVs, but this goal could be achieved by employing two in-house MDVs (vB5 and Vero-15). In immunization studies, mice received two doses of Vero cell-derived inactivated H5N1 and H7N9 whole virus antigens adjuvanted with alum and developed robust antibody responses.
Keywords: Vero cell-derived influenza vaccine; master donor virus; pandemic preparedness.